Prostate Cancer Risk Not Linked With Circulating Sex Hormones In The Blood
Main Category: Prostate / Prostate CancerAlso Included In: Endocrinology; Sexual Health / STDs
Article Date: 30 Jan 2008 - 3:00 PDT
| Patient / Public: | ![]() |
4 (1 votes) |
| Healthcare Prof: | ![]() |
Sex hormones circulating in the blood do not appear to be associated with prostate cancer risk, according to data from 18 prior studies. The analysis was published online January 29 in the Journal of the National Cancer Institute.
Having high levels of male sex hormones, known as androgens, has long been hypothesized as a risk factor for prostate cancer. Nearly two dozen prospective studies have examined the relationship between circulating sex hormones and prostate cancer risk, but the results have been inconsistent.
Andrew Roddam, D.Phil., of the University of Oxford in England and colleagues at the Endogenous Hormones and Prostate Cancer Collaborative Group collected the original data from 18 studies and analyzed it to determine the relationship between blood levels of sex hormones and prostate cancer. The pooled data included 3,886 men with prostate cancer and 6,438 controls.
The researchers found no association between prostate cancer risk and blood levels of different forms of testosterone or estrogen.
"The results of this collaborative analysis of the existing worldwide data on the associations between endogenous hormone concentrations and prostate cancer risk indicate that circulating concentrations of androgens and [estrogens] do not appear to be associated with the risk of prostate cancer," the authors write.
In an accompanying editorial, Paul Godley, M.D., Ph.D., and colleagues at the University of North Carolina at Chapel Hill commend the authors for collaborating on this analysis, and they encourage researchers to use the results as an opportunity to shift the focus of prostate cancer research.
"The study obliges the scientific community to move past a seductive, clinically relevant, and biologically plausible hypothesis and get on with the difficult task of exploring, analyzing, and characterizing modifiable risk factors for prostate cancer," the editorialists write.
###
Citation:
* Article: Endogenous Hormones and Prostate Cancer Collaborative Group. Endogenous Sex Hormones and Prostate Cancer: A Collaborative Analysis of 18 Prospective Studies. J Natl Cancer Inst 2008; 100: 170-183
* Editorial: Carpenter WR, Robinson WR, Godley PA. Getting Over Testosterone: Postulating a Fresh Start for Etiologic Studies of Prostate Cancer. J Natl Cancer Inst 2008; 100:158-159
The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Visit the Journal online at http://jnci.oxfordjournals.org/.
Source: Liz Savage
Journal of the National Cancer Institute
Visit our prostate / prostate cancer section for the latest news on this subject.
MLA
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/95572.php>
APA
http://www.medicalnewstoday.com/releases/95572.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




